M. Sarbia et al., Expression of apoptosis-regulating proteins and outcome of esophageal cancer patients treated by combined therapy modalities, CLIN CANC R, 4(12), 1998, pp. 2991-2997
The present study retrospectively examines the correlation between the outc
ome of patients with locally advanced esophageal squamous cell carcinoma (L
AEC) after multimodal treatment (radiochemotherapy +/- surgery) and the exp
ression of apoptosis-regulating proteins in pretherapeutic biopsies.
Thirty-eight patients with LAEC who took part in a prospective multicentric
trial received radiochemotherapy, optionally followed by surgery. Pretreat
ment tumor biopsies were immunohistochemically investigated for expression
of p53, Bcl-2, Bar (bcl-2-associated X protein), and Bcl-X-L (bcl-2-related
X protein),
The overall expression of p53, Bcl-2, Bar, and Bcl-X-L was 52.6, 57.9, 100,
and 97.4% respectively, Tumors without p53 expression and tumors with weak
Bcl-X-L expression showed response to chemotherapy more frequently (55.6 a
nd 52.6%, respectively) than tumors positive for p53 expression and tumors
with strong Bcl-X-L expression (30.0 and 31.6%, respectively); however, the
se differences did not attain statistical significance. No correlations wer
e found between the expression of Bcl-2 and Bar and the response to chemoth
erapy. In patients treated by radiochemotherapy and surgery, p53-negative t
umors showed a significantly better outcome than p53-positive tumors (mean
survival, 31.1 months versus 11.3 months; P = 0.0378), Additionally, a more
favorable outcome was observed in tumors positive for Bcl-2 (not significa
nt), whereas no differences in survival were observed in relation to the ex
pression of Bar or Bcl-X-L. No differences in survival were observed in pat
ients treated by radiochemotherapy without subsequent resection therapy in
relation to the expression of apoptosis-regulating proteins.
Immunohistochemical examination of pretherapeutic tumor biopsies for expres
sion of apoptosis-regulating proteins may help to identify patients with LA
EC who may benefit from multimodal treatment and those who may not.